Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025
Crinetics Pharmaceuticals (CRNX) has scheduled its fourth quarter and full year 2024 financial results announcement for Thursday, February 27, 2025, after market close. The company will host a conference call at 4:30 p.m. ET, featuring management discussion of financial results and a business update.
Interested parties can join via phone using domestic (1-800-267-6316) or international (1-203-518-9783) dial-in numbers with Conference ID: CRNXQ4. Alternatively, participants can access a live webcast through the Events section of Crinetics' website. Participants are advised to connect 15 minutes before the call. The webcast will be archived on the company's Investor Relations section.
Crinetics Pharmaceuticals (CRNX) ha programmato l'annuncio dei risultati finanziari del quarto trimestre e dell'intero anno 2024 per giovedì 27 febbraio 2025, dopo la chiusura del mercato. L'azienda ospiterà una conferenza telefonica alle 16:30 ET, durante la quale la direzione discuterà i risultati finanziari e fornirà un aggiornamento sull'attività.
Le parti interessate possono partecipare telefonicamente utilizzando i numeri nazionali (1-800-267-6316) o internazionali (1-203-518-9783) con ID Conferenza: CRNXQ4. In alternativa, i partecipanti possono accedere a una diretta streaming attraverso la sezione Eventi del sito web di Crinetics. Si consiglia ai partecipanti di collegarsi 15 minuti prima della chiamata. La diretta sarà archiviata nella sezione Relazioni con gli Investitori dell'azienda.
Crinetics Pharmaceuticals (CRNX) ha programado el anuncio de sus resultados financieros del cuarto trimestre y del año completo 2024 para el jueves 27 de febrero de 2025, después del cierre del mercado. La compañía realizará una llamada de conferencia a las 4:30 p.m. ET, en la que la gerencia discutirá los resultados financieros y proporcionará una actualización sobre el negocio.
Las partes interesadas pueden unirse por teléfono utilizando los números nacionales (1-800-267-6316) o internacionales (1-203-518-9783) con ID de Conferencia: CRNXQ4. Alternativamente, los participantes pueden acceder a una transmisión en vivo a través de la sección de Eventos del sitio web de Crinetics. Se aconseja a los participantes que se conecten 15 minutos antes de la llamada. La transmisión se archivará en la sección de Relaciones con Inversores de la compañía.
크리네틱스 제약(CRNX)은 2025년 2월 27일 목요일 시장 마감 후 2024년 4분기 및 연간 재무 결과 발표를 예정하고 있습니다. 회사는 동부 표준시 기준 오후 4시 30분에 경영진이 재무 결과에 대해 논의하고 비즈니스 업데이트를 제공하는 전화 회의를 개최합니다.
관심 있는 당사자는 전화로 참여할 수 있으며, 국내 전화번호 (1-800-267-6316) 또는 국제 전화번호 (1-203-518-9783)를 사용하여 참석할 수 있으며, 회의 ID는 CRNXQ4입니다. 또는 참가자는 크리네틱스 웹사이트의 이벤트 섹션을 통해 라이브 웹캐스트에 접속할 수 있습니다. 참가자는 회의 15분 전에 연결할 것을 권장합니다. 웹캐스트는 회사의 투자자 관계 섹션에 보관됩니다.
Crinetics Pharmaceuticals (CRNX) a programmé l'annonce de ses résultats financiers du quatrième trimestre et de l'année complète 2024 pour le jeudi 27 février 2025, après la clôture du marché. L'entreprise animera une conférence téléphonique à 16h30 ET, au cours de laquelle la direction discutera des résultats financiers et fournira une mise à jour sur l'activité.
Les parties intéressées peuvent participer par téléphone en utilisant les numéros nationaux (1-800-267-6316) ou internationaux (1-203-518-9783) avec l'ID de conférence : CRNXQ4. Alternativement, les participants peuvent accéder à un webcast en direct via la section Événements du site Web de Crinetics. Il est conseillé aux participants de se connecter 15 minutes avant l'appel. Le webcast sera archivé dans la section Relations Investisseurs de l'entreprise.
Crinetics Pharmaceuticals (CRNX) hat die Bekanntgabe seiner finanziellen Ergebnisse für das vierte Quartal und das Gesamtjahr 2024 für Donnerstag, den 27. Februar 2025, nach Marktschluss angesetzt. Das Unternehmen wird um 16:30 Uhr ET eine Telefonkonferenz abhalten, in der das Management die finanziellen Ergebnisse und ein Update zum Geschäft besprechen wird.
Interessierte Parteien können telefonisch über die nationalen Nummern (1-800-267-6316) oder internationale Nummern (1-203-518-9783) mit der Konferenz-ID: CRNXQ4 teilnehmen. Alternativ können Teilnehmer über den Bereich Veranstaltungen auf der Website von Crinetics auf einen Live-Webcast zugreifen. Es wird empfohlen, dass sich die Teilnehmer 15 Minuten vor der Konferenz einwählen. Der Webcast wird im Bereich Investor Relations des Unternehmens archiviert.
- None.
- None.
SAN DIEGO, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report fourth quarter and full year 2024 financial results on Thursday, February 27, 2025 after the market closes. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update.
Conference Call & Webcast
Thursday, February 27 @ 4:30 p.m. ET
Domestic: 1-800-267-6316
International: 1-203-518-9783
Conference ID: CRNXQ4
Webcast: Participants can use the dial-in numbers above OR access the live webcast via a direct link (HERE) or by visiting the Events section of the Crinetics website. To ensure a timely connection, it is recommended that participants connect at least 15 minutes prior to the scheduled start of the call.
The webcast will be archived on the Investor Relations section of www.crinetics.com.
About Crinetics Pharmaceuticals
Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. Crinetics’ lead development candidate, paltusotine, is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Atumelnant is currently in development for congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome. All of the company’s drug candidates are orally delivered, small molecule, new chemical entities resulting from in-house drug discovery efforts, including additional discovery programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves’ disease (including thyroid eye disease), diabetes, obesity and GPCR-targeted oncology indications.
Investors:
Gayathri Diwakar
Head of Investor Relations
gdiwakar@crinetics.com
(858) 345-6340
Media:
Natalie Badillo
Head of Corporate Communications
nbadillo@crinetics.com
(858) 345-6075
FAQ
When will Crinetics Pharmaceuticals (CRNX) release Q4 and full year 2024 earnings?
What time is the CRNX Q4 2024 earnings conference call?
How can investors access CRNX's Q4 2024 earnings call?
Where can I find the replay of CRNX's Q4 2024 earnings webcast?
